13 October 2008
DSM invests in incubator to strengthen position in biomedical materials
DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announces
that it has made an investment in the new business incubator in the field of
medical devices Accelerated Technologies II, L.P. (ATP). The investment
further strengthens DSM’s position in the biomedical materials market, one of
the Emerging Business Areas defined in its Vision 2010 – Building on Strengths
strategy. Financial details will not be disclosed.
26 September 2008
DSM invests in intelligent medication packaging
DSM Venturing, the
corporate venturing unit of Royal DSM N.V., today announces that it has made
an equity investment in The Compliers Group International B.V. (TCG). The
Netherlands-based company focuses on the development of smart pharmaceutical
packaging solutions that contain microchips which enable the monitoring of a
patient’s therapy compliance. Financial details of the investment will not be
disclosed.
27 August 2008
DSM invests in food ingredients developer Provexis plc
DSM
Venturing, the corporate venturing unit of Royal DSM N.V., today announces
that it has acquired an equity stake of 29.3% in Provexis plc, an AIM listed
company that develops and licenses ingredients for the functional food,
medical food and dietary supplement market. The investment makes DSM the
largest shareholder of Provexis.
6 March 2008
DSM invests in innovative treatment against infectious disease
DSM
Venturing, the corporate venturing unit of Royal DSM N.V., today announced
that it has made an equity investment in the Dutch company IQ Therapeutics
B.V. The company develops antibody based products for biodefense and for the
prevention and treatment of infectious diseases. DSM Venturing will hold a
significant minority share in IQ Therapeutics.
5 March 2008
DSM invests in development of bio-based materials in China
DSM
Venturing, the corporate venturing unit of Royal DSM N.V., today announced
that it has participated in a USD 20 million financing round in Tianjin Green
Bio-Science Co., Ltd (China). The proceeds will be used to build China’s
largest manufacturing plant for Polyhydroxyalkanoates (PHA) in the Tianjin
Economic Development Area (TEDA).
